Daily Sepsis Research Analysis
Analyzed 10 papers and selected 3 impactful papers.
Summary
Three papers collectively advance sepsis science from bench to bedside: a mechanistic study uncovers an ADAR1–miR-122–XIAP axis in macrophage exosomes that protects the heart in septic cardiomyopathy; a comprehensive review positions CX3CR1 as a cell type–specific target for precision immunotherapy; and a large population cohort shows markedly elevated serious infection and sepsis rates with excess mortality in Sjögren’s disease.
Research Themes
- Immune modulation and exosome-mediated signaling in sepsis
- Precision immunotherapy targets (CX3CR1) across immune subsets
- Infection burden and sepsis risk stratification in autoimmune disease
Selected Articles
1. Therapeutic potential of ADAR1-regulated macrophage exosomes for improving myocardial damage in septic cardiomyopathy.
In a murine sepsis model, macrophage ADAR1 overexpression induced M2 polarization, reduced myocardial inflammation, and decreased cardiomyocyte apoptosis. ADAR1 modulated exosomal miR-122, which targeted XIAP to enhance cardiomyocyte survival, defining an ADAR1–miR-122–XIAP axis with therapeutic promise for septic cardiomyopathy.
Impact: Identifies a previously unrecognized exosomal regulatory axis linking macrophage ADAR1 to cardiomyocyte survival in sepsis, suggesting a tractable therapeutic pathway.
Clinical Implications: While preclinical, the ADAR1–miR-122–XIAP axis supports development of exosome-based or small-molecule strategies to modulate macrophage polarization and protect the heart in septic cardiomyopathy.
Key Findings
- Macrophage ADAR1 overexpression induces anti-inflammatory M2 polarization in a murine sepsis model.
- ADAR1 reduces myocardial inflammation and inhibits cardiomyocyte apoptosis during sepsis.
- ADAR1 regulates exosomal miR-122; exosomal miR-122 targets XIAP to modulate cardiomyocyte survival, defining an ADAR1–miR-122–XIAP axis.
Methodological Strengths
- Mechanistic validation in an in vivo sepsis model linking immune cell polarization to cardiomyocyte survival
- Exosome- and miRNA-centered pathway identification with a defined target (XIAP)
Limitations
- Findings are preclinical and limited to murine models; human validation is absent
- Translational challenges for exosome delivery, dosing, and off-target effects remain unresolved
Future Directions: Validate the ADAR1–miR-122–XIAP axis in human septic cardiomyopathy, optimize exosome delivery or small-molecule modulators, and test efficacy in large-animal models.
BACKGROUND: Sepsis-induced cardiomyopathy (SICM) is a critical cardiovascular complication characterized by cardiac dysfunction and high mortality. The molecular mechanisms that underlie SICM remain elusive, and effective therapies are limited. RESULTS: Here, we report a pivotal role for adenosine deaminases acting on RNA-1 (ADAR1) in modulating macrophage polarization and exosome-mediated intercellular communication, which ameliorates myocardial damage in SICM. We determined that ADAR1 overexpression in macrophages promotes an anti-inflammatory M2 phenotype, reduces myocardial inflammation, and inhibits cardiomyocyte apoptosis in a murine model of sepsis. Mechanistically, ADAR1 regulates the level of microRNA-122 (miR-122) in macrophage-derived exosomes. Exosomal miR-122 targets X-linked inhibitor of apoptosis protein (XIAP), modulating cardiomyocyte survival. CONCLUSIONS: Our study reveals a novel ADAR1-miR-122-XIAP axis in macrophage exosomes that protects against sepsis-induced myocardial injury, offering a potential disease modulation strategy for SICM.
2. CX3CR1-mediated immune networks in sepsis: implications for precision therapy.
This review synthesizes evidence that CX3CR1 differentially shapes sepsis immunity across monocytes/macrophages, NK cells, and T cells, with expression levels correlating with survival. Preclinical data support cell type–specific CX3CR1 modulation as a precision strategy for sepsis therapy.
Impact: Frames CX3CR1 as a tractable, cell type–specific immunoregulatory target, guiding biomarker development and therapeutic design for precision sepsis care.
Clinical Implications: Although clinical trials are lacking, CX3CR1 expression may inform risk stratification and patient selection, and cell type–specific modulation could be tested in early-phase sepsis trials.
Key Findings
- CX3CR1 orchestrates proliferation, differentiation, activation, migration, and survival across monocytes/macrophages, NK cells, and T cells in sepsis.
- Heterogeneous CX3CR1 expression underlies dual pro- and anti-inflammatory effects, with expression levels correlating with patient survival.
- Cell type–specific CX3CR1 targeting shows efficacy in preclinical sepsis models, supporting precision therapeutic strategies.
Methodological Strengths
- Comprehensive, cell subset–resolved synthesis spanning molecular to preclinical evidence
- Clear therapeutic framing of CX3CR1 with biomarker implications
Limitations
- Narrative review without formal systematic methods or meta-analysis
- Translation to clinical endpoints remains unproven; human interventional data are sparse
Future Directions: Standardize CX3CR1 measurement as a biomarker, map cell type–specific roles in human sepsis, and design early-phase trials of selective CX3CR1 modulators.
Sepsis is a life-threatening syndrome characterized by profound immune dysregulation in response to infection, and it remains a major cause of mortality worldwide. The CX3C chemokine receptor 1 (CX3CR1) has emerged as a pivotal regulator of sepsis-induced immune dysregulation, orchestrating the proliferation, differentiation, activation, migration, and survival of various immune cell populations, including monocytes/macrophages, natural killer cells (NK), and T cells. Emerging evidence highlights that the diverse expression patterns of CX3CR1 within distinct immune cell subsets determine its dual pro-inflammatory and anti-inflammatory effects, and CX3CR1 expression level is closely correlated with patient survival in sepsis. In addition, targeted modulation of CX3CR1 in specific immune cell types has shown promising efficacy in preclinical sepsis models. This review provides a comprehensive overview of the molecular immunoregulatory networks governed by CX3CR1, its heterogenous functions across different immune subsets, and recent advances in CX3CR1-targeted therapies, highlighting cell type-specific interventions as promising strategies for precision sepsis treatment.
3. Frequency and Impact of Serious Infections in Hospitalised Patients with Sjögren's Disease: A Longitudinal Cohort Study.
In a population-level matched cohort, hospitalized Sjögren’s disease patients had substantially higher serious infection rates across multiple categories, including a sixfold increase in sepsis, and experienced nearly double the mortality after serious infection. Secondary (associated) SjD carried higher infection risk than primary SjD.
Impact: Provides robust, longitudinal evidence quantifying excess serious infection and sepsis risk with mortality impact in Sjögren’s disease, informing prevention and surveillance strategies.
Clinical Implications: Supports intensified vaccination, infection surveillance, early sepsis recognition, and careful immunosuppression management in Sjögren’s disease, especially for secondary SjD.
Key Findings
- Serious infections were more frequent in SjD versus controls (OR 1.87), with a fourfold higher incidence rate (IRR 4.28).
- Marked increases were seen for pneumonia (IRR 4.01), urogenital (IRR 3.06), skin/soft tissue (IRR 5.22), opportunistic infections (IRR 6.93), and sepsis (IRR 6.15).
- Mortality after serious infection was nearly doubled in SjD versus controls (MR ratio 1.89); secondary SjD had higher infection risk than primary SjD.
Methodological Strengths
- Population-level dataset with age- and sex-matched controls over 35 years
- Validated algorithm for serious infection classification and linkage to death registry
Limitations
- Retrospective administrative coding may introduce misclassification and residual confounding
- Limited clinical granularity (e.g., disease activity, immunosuppressive dosing) not captured in administrative data
Future Directions: Prospective cohorts incorporating disease activity, medication exposure, and microbiology to refine risk models and test targeted prevention bundles.
INTRODUCTION: As little is known about the risk, type and severity of infections in patients with Sjögren's disease (SjD), we compared the frequency and impact of serious infections (SI) between hospitalised patients with SjD and controls (Co). METHODS: Population-level observational study of patients with SjD (n = 692, 87.9% female, age 67 years) identified in the Hospital Morbidity Data Collection (HDMC) in Western Australia (WA) between 1980 and 2015 by diagnostic codes (ICD-9 CM 710.2, ICD10-AM M35.0) and age- and gender-matched controls free of rheumatic disease (n = 3737, 87.5% female, age 67 years). SI were defined by a validated algorithm and primary SjD, as the absence of other autoimmune rheumatic disease. Odds ratios (OR), incidence rates (IR) per 100 person-years (PY) and IR ratios (IRR) with 95% CI for SI were estimated. HDMC data were linked to WA Death Registry to evaluate the impact of SI on mortality rates (MR) per 100 PY and Kaplan-Meier survival estimates. RESULTS: Serious infections occurred more in patients with SjD (OR 1.87, CI 1.59, 2.21, p < 0.01) with a fourfold higher IR for SI (IRR 4.28, CI 4.02-4.56) and increased IRR for pneumonia (4.01, CI 3.50-4.60), urogenital (3.06, CI 2.73-3.43), skin/soft tissue (5.22, CI 4.60-5.90), opportunistic infections (6.93, CI 5.77-8.32) and sepsis (6.15, CI 4.87-7.74) (all p < 0.01). The MR for patients with SjD with SI was almost twice that for Co with SI (MR ratio 1.89, CI 1.65-2.16). Patients with associated SjD (n = 270, 39%) had increased OR (2.05, CI 1.49-2.82) and IRR (1.61, CI 1.44-1.79) for SI compared to patients with primary SjD (n = 422, 61%). Few differences in SI existed between patients with SjD associated with rheumatoid arthritis (n = 197) or SLE (n = 79). CONCLUSIONS: SI occurred at a higher rate in all patients with SjD and was associated with increased long-term mortality. These results emphasize the increased susceptibility to and impact of SI for both patients with primary and secondary SjD.